US Patent

US11819533 — Compositions and methods for the treatment of fungal infections

Method of Use · Assigned to Cidara Therapeutics Inc · Expires 2038-07-11 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions containing CD101, such as CD101 acetate, for intravenous administration to treat fungal infections like candidiasis.

USPTO Abstract

The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.

Drugs covered by this patent

rezafungin-acetate (REZAFUNGIN ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3566`	—	rezafungin-acetate

Patent Metadata

Patent number: US11819533
Jurisdiction: US
Classification: Method of Use
Expires: 2038-07-11
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Cidara Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.